# Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease

> clinical trial · VERIFIED · 2026-07-17

Status: RECRUITING · Sponsor: University of California, Los Angeles · Condition: Cushing Disease

- Company: University of California, Los Angeles
- Sector: Cushing Disease
- Primary source: https://clinicaltrials.gov/study/NCT05971758

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.